Trial · NCT04313634
Results by group23
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 23
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in C-terminal Telopeptide of Type I Collagen [CTX] | Dasatinib Plus Quercetin Treatment Goup | -4.1 | Full Range -28.1 to 114.6 | percent change | |
| Change in C-terminal Telopeptide of Type I Collagen [CTX] | Fisetin Treatment Group | 13.7 | Full Range -42.7 to 61.0 | percent change | |
| Change in C-terminal Telopeptide of Type I Collagen [CTX] | Untreated Control Group | -7.7 | Full Range -42.4 to 22.5 | percent change | |
| Change in Bone Turnover Markers | Dasatinib Plus Quercetin Treatment Goup | 0.8 | Full Range -39.6 to 113.5 | percentage change of P1NP | |
| Change in Bone Turnover Markers | Fisetin Treatment Group | -31.9 | Full Range -74.0 to 23.3 | percentage change of P1NP | |
| Change in Bone Turnover Markers | Untreated Control Group | -15.2 | Full Range -55.0 to 59.8 | percentage change of P1NP | |
| Change in Bone Turnover Markers | Dasatinib Plus Quercetin Treatment Goup | 4.2 | Full Range -61.4 to 1480 | percentage change of P1NP | |
| Change in Bone Turnover Markers | Untreated Control Group | -12.1 | Full Range -58.0 to 95.9 | percentage change of P1NP | |
| Change in Bone Turnover Markers | Dasatinib Plus Quercetin Treatment Goup | -8.6 | Full Range -48.1 to 130.9 | percentage change of P1NP | |
| Change in Bone Turnover Markers | Fisetin Treatment Group | 4.5 | Full Range -34.8 to 29.7 | percentage change of P1NP | |
| Change in Bone Turnover Markers | Untreated Control Group | 0.1 | Full Range -49.2 to 95.2 | percentage change of P1NP | |
| Change in Bone Mineral Density (BMD) | Dasatinib Plus Quercetin Treatment Goup | Lumbar Spine | -0.2 | Full Range -3.1 to 6.2 | percentage of change in BMD |
| Change in Bone Mineral Density (BMD) | Fisetin Treatment Group | Lumbar Spine | 0 | Full Range -1.5 to 8.9 | percentage of change in BMD |
| Change in Bone Mineral Density (BMD) | Untreated Control Group | Lumbar Spine | 0.5 | Full Range -10.4 to 6.8 | percentage of change in BMD |
| Change in Bone Mineral Density (BMD) | Dasatinib Plus Quercetin Treatment Goup | Hip (Femoral neck ) | -0.3 | Full Range -4.8 to 4.0 | percentage of change in BMD |
| Change in Bone Mineral Density (BMD) | Fisetin Treatment Group | Hip (Femoral neck ) | -0.9 | Full Range -3.7 to 2.0 | percentage of change in BMD |
| Change in Bone Mineral Density (BMD) | Untreated Control Group | Hip (Femoral neck ) | -0.5 | Full Range -6.0 to 19.2 | percentage of change in BMD |
| Change in Bone Mineral Density (BMD) | Dasatinib Plus Quercetin Treatment Goup | Radius | 0.4 | Full Range -3.0 to 6.9 | percentage of change in BMD |
| Change in Bone Mineral Density (BMD) | Fisetin Treatment Group | Radius | 0.7 | Full Range -12.1 to 5.7 | percentage of change in BMD |
| Change in Bone Mineral Density (BMD) | Untreated Control Group | Radius | 0.2 | Full Range -4.7 to 12.9 | percentage of change in BMD |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04313634/results